

Jillian H Broadbear

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8780760/publications.pdf>

Version: 2024-02-01

62
papers

1,053
citations

394286

19
h-index

454834

30
g-index

62
all docs

62
docs citations

62
times ranked

1160
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on $\hat{\mu}$ -opioid agonists in the mouse writhing assay. <i>Psychopharmacology</i> , 1994, 115, 311-319.	1.5	126
2	Modulation of anxiety behavior in the elevated plus maze using peptidic oxytocin and vasopressin receptor ligands in the rat. <i>Journal of Psychopharmacology</i> , 2012, 26, 532-542.	2.0	72
3	Self-administration of fentanyl, cocaine and ketamine: effects on the pituitary/adrenal axis in rhesus monkeys. <i>Psychopharmacology</i> , 2004, 176, 398-406.	1.5	70
4	Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test. <i>Psychopharmacology</i> , 2010, 210, 35-43.	1.5	59
5	Risky drug use and effects on sleep quality and daytime sleepiness. <i>Human Psychopharmacology</i> , 2015, 30, 356-363.	0.7	42
6	Corticotropin-Releasing Hormone Antagonists, Astressin B and Antalarmin: Differing Profiles of Activity in Rhesus Monkeys. <i>Neuropsychopharmacology</i> , 2004, 29, 1112-1121.	2.8	39
7	Receptor reserve and affinity of mu opioid agonists in mouse antinociception: correlation with receptor binding. <i>Life Sciences</i> , 1995, 57, 2113-2125.	2.0	38
8	Effects of modafinil on simulator driving and self-assessment of driving following sleep deprivation. <i>Human Psychopharmacology</i> , 2008, 23, 681-692.	0.7	33
9	Examining the role of oxytocin in the interoceptive effects of 3,4-methylenedioxyamphetamine (MDMA, "ecstasy") using a drug discrimination paradigm in the rat. <i>Addiction Biology</i> , 2011, 16, 202-214.	1.4	32
10	Missed diagnosis: The emerging crisis of borderline personality disorder in older people. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 1139-1145.	1.3	32
11	Borderline personality disorder and depressive disorder. <i>Australasian Psychiatry</i> , 2019, 27, 573-577.	0.4	32
12	BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism. <i>European Journal of Pharmacology</i> , 2005, 509, 117-125.	1.7	28
13	Avoiding Misdiagnosis When Auditory Verbal Hallucinations Are Present in Borderline Personality Disorder. <i>Journal of Nervous and Mental Disease</i> , 2019, 207, 1048-1055.	0.5	25
14	Self-administration of methohexital, midazolam and ethanol: effects on the pituitary/adrenal axis in rhesus monkeys. <i>Psychopharmacology</i> , 2005, 178, 83-91.	1.5	23
15	Ecstasy use and self-reported disturbances in sleep. <i>Human Psychopharmacology</i> , 2011, 26, 508-516.	0.7	23
16	Noncontingent and Response-Contingent Intravenous Ethanol Attenuates the Effect of Naltrexone on Hypothalamic-Pituitary-Adrenal Activity in Rhesus Monkeys. <i>Alcoholism: Clinical and Experimental Research</i> , 2004, 28, 566-571.	1.4	21
17	Oxytocinergic regulation of endogenous as well as drug-induced mood. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 119, 61-71.	1.3	21
18	Antalarmin, a putative CRH-R1 antagonist, has transient reinforcing effects in rhesus monkeys. <i>Psychopharmacology</i> , 2002, 164, 268-276.	1.5	20

#	ARTICLE	IF	CITATIONS
19	Structural Determinants of Opioid Activity in Derivatives of 14-Aminomorphinones: Effect of Substitution in the Aromatic Ring of Cinnamoylaminomorphinones and Codeinones. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5333-5338.	2.9	20
20	What is the clinical significance of chronic emptiness in borderline personality disorder?. <i>Australasian Psychiatry</i> , 2018, 26, 88-91.	0.4	20
21	3-Alkyl Ethers of Clocinnamox: Delayed Long-Term μ -Antagonists with Variable μ Efficacy. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 3493-3498.	2.9	19
22	Male and female ecstasy users: Differences in patterns of use, sleep quality and mental health outcomes. <i>Drug and Alcohol Dependence</i> , 2013, 132, 223-230.	1.6	17
23	An exploration of self-compassion and self-criticism in the context of personal recovery from borderline personality disorder. <i>Australasian Psychiatry</i> , 2019, 27, 56-59.	0.4	17
24	Long-Term Antihyperalgesic and Opioid-Sparing Effects of 5-Day Ketamine and Morphine Infusion (Burst Ketamine) in Diabetic Neuropathic Rats. <i>Pain Medicine</i> , 2015, 16, 1781-1793.	0.9	14
25	Sex differences in the pituitary-adrenal response following acute antidepressant treatment in sheep. <i>Psychopharmacology</i> , 2004, 171, 450-457.	1.5	13
26	14-O-Cinnamoylnaltrexone and Related Dihydrocodeinones are Mu Opioid Receptor Partial Agonists with Predominant Antagonist Activity. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1553-1557.	2.9	12
27	Coroners' investigations of suicide in Australia: The hidden toll of borderline personality disorder. <i>Journal of Psychiatric Research</i> , 2020, 129, 241-249.	1.5	12
28	Reviewing the clinical significance of 'fear of abandonment' in borderline personality disorder. <i>Australasian Psychiatry</i> , 2019, 27, 60-63.	0.4	11
29	6N-Cinnamoyl- μ -naltrexamine and its p-nitro derivative. High efficacy μ -opioid agonists with weak antagonist actions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1996, 6, 167-172.	1.0	10
30	Acute MDMA administration alters the distribution and circadian rhythm of wheel running activity in the rat. <i>Brain Research</i> , 2010, 1359, 128-136.	1.1	10
31	Cinnamoyl Derivatives of 7 α -Amino- and 7 β -(Aminomethyl)-N-(cyclopropylmethyl)-6,14-endo-ethanotetrahydronoropipavines are High-Potency Opioid Antagonists. <i>Helvetica Chimica Acta</i> , 2000, 83, 3122-3130.	1.0	8
32	Fumaroylamino-4,5-epoxymorphinans and Related Opioids with Irreversible μ Opioid Receptor Antagonist Effects. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9868-9874.	2.9	8
33	Ecstasy and sleep disturbance: Progress towards elucidating a role for the circadian system. <i>Sleep and Biological Rhythms</i> , 2012, 10, 3-13.	0.5	8
34	Consumer perspectives on personal recovery and borderline personality disorder. <i>Journal of Mental Health Training, Education and Practice</i> , 2017, 12, 350-359.	0.3	8
35	Opioid agonist effects on mouse writhing after irreversible mu receptor blockade with clocinnamox.. <i>Experimental and Clinical Psychopharmacology</i> , 1995, 3, 323-329.	1.3	7
36	Antidepressants, sex steroids and pituitary/adrenal response in sheep. <i>Psychopharmacology</i> , 2004, 175, 247-55.	1.5	7

#	ARTICLE	IF	CITATIONS
37	14 β -Arylpropionylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and Related Opioids. Further Examples of Pseudoirreversible μ Opioid Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6926-6930.	2.9	7
38	Potential Irreversible Ligands for Opioid Receptors. Cinnamoyl Derivatives of μ -Naltrexamine. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 48, 192-196.	1.2	7
39	Clinician perspectives on recovery and borderline personality disorder. <i>Journal of Mental Health Training, Education and Practice</i> , 2017, 12, 199-209.	0.3	7
40	Developments in diagnosis and treatment of people with borderline personality disorder. <i>Current Opinion in Psychiatry</i> , 2020, 33, 441-446.	3.1	7
41	Glucocorticoid-reinforced responding in the rhesus monkey. <i>Psychopharmacology</i> , 1999, 147, 46-55.	1.5	6
42	Role of Sex and Sex Steroids in Mediating Pituitary-Adrenal Responses to Acute Buspirone Treatment in Sheep. <i>Journal of Neuroendocrinology</i> , 2005, 17, 051017082542002.	1.2	6
43	Corticotropin-releasing hormone in nonhuman primates. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 2303.	3.0	6
44	Evaluation of a novel risk assessment method for self-harm associated with Borderline Personality Disorder. <i>Australasian Psychiatry</i> , 2017, 25, 460-465.	0.4	6
45	Pharmacokinetic comparison of a combination tablet of enalapril and hydrochlorothiazide with enalapril and hydrochlorothiazide tablets administered together and separately. <i>Biopharmaceutics and Drug Disposition</i> , 1991, 12, 447-455.	1.1	5
46	Dysfunctional overnight memory consolidation in ecstasy users. <i>Journal of Psychopharmacology</i> , 2014, 28, 751-762.	2.0	5
47	Emergency department utilisation by patients with a diagnosis of borderline personality disorder: An acute response to a chronic disorder. <i>EMA - Emergency Medicine Australasia</i> , 2022, 34, 731-737.	0.5	5
48	Role of metabolic risk factors in cardiovascular prognosis of systemic hypertension. <i>American Journal of Cardiology</i> , 1990, 65, H43-H45.	0.7	4
49	Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users. <i>Journal of Psychopharmacology</i> , 2009, 23, 759-774.	2.0	4
50	Evaluation of changes in prescription medication use after a residential treatment programme for borderline personality disorder. <i>Australasian Psychiatry</i> , 2016, 24, 583-588.	0.4	4
51	MDMA induces Per1, Per2 and c-fos gene expression in rat suprachiasmatic nuclei. <i>Psychopharmacology</i> , 2012, 220, 835-843.	1.5	3
52	Guest editorial. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 119, 1-2.	1.3	3
53	The impact of COVID-19 lockdown on the well-being of clients of a specialist personality disorder service. <i>Australasian Psychiatry</i> , 2022, 30, 235-238.	0.4	3
54	Ten-week Intensive Group Program (IGP) for borderline personality disorder: making the case for more accessible and affordable psychotherapy. <i>Evidence-Based Mental Health</i> , 2021, 24, e1-e1.	2.2	2

#	ARTICLE	IF	CITATIONS
55	Disjunction in the subjective and objective measurement of co-occurring depression in borderline personality disorder – Implications for diagnosis. <i>Australasian Psychiatry</i> , 2022, 30, 481-485.	0.4	2
56	Disturbed sleep in ecstasy users reported by partners/roommates. <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 587-588.	1.3	1
57	Confidence of psychiatry trainees in meeting the needs of borderline personality disorder in comparison with schizophrenia. <i>Australasian Psychiatry</i> , 2021, 29, 103985622199265.	0.4	1
58	Discriminative stimulus properties of the 5-HT1A receptor biased agonists NLX-101 and F13714, in rats trained to discriminate 8-OH-DPAT from saline. <i>Behavioural Pharmacology</i> , 2021, Publish Ahead of Print, 652-659.	0.8	1
59	Assessment of peer-conceptualised, written and led single-session group interventions for carers supporting a person with borderline personality disorder. <i>Advances in Mental Health</i> , 0, , 1-12.	0.3	1
60	Hallucinations in BPD: More prevalent than community sample study suggests?. <i>British Journal of Psychiatry</i> , 2017, 211, 250-251.	1.7	0
61	Editorial: Preface and Overview Second International MDMA –Ecstasy™ Conference in Australasia: Monash University, Melbourne, Australia. <i>The Open Addiction Journal</i> , 2011, 4, 1-3.	0.5	0
62	The impact of COVID-19 lockdown on the well-being of mental healthcare providers working in a specialist clinic for personality disorder. <i>Australian Psychologist</i> , 0, , 1-7.	0.9	0